309 related articles for article (PubMed ID: 33626447)
1. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography.
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
J Pharm Biomed Anal; 2021 Apr; 197():113960. PubMed ID: 33626447
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an analytical method for trace-level quantification of genotoxic nitrosamine impurities in losartan and hydrochlorothiazide fixed-dose combination tablets using ultra performance liquid chromatography triple quadrupole mass spectrometry.
Patel R; Purohit S; Solanki R; Khunt D; Patel C; Patel R; Parikh S
Rapid Commun Mass Spectrom; 2023 Apr; 37(8):e9488. PubMed ID: 36740827
[TBL] [Abstract][Full Text] [Related]
4. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.
Shaik KM; Sarmah B; Wadekar GS; Kumar P
Crit Rev Anal Chem; 2022; 52(1):53-71. PubMed ID: 32691615
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive UHPLC-MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation.
Jireš J; Douša M; Gibala P; Doubský J; Pěček D; Mervart D; Kluk A; Veseli A; Kalášek S; Řezanka P
J Pharm Biomed Anal; 2024 Jan; 238():115861. PubMed ID: 37976984
[TBL] [Abstract][Full Text] [Related]
6. Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography Tripple Quadrupole Mass Spectrometry.
Solanki R; Wadhwana P; Patel R; Gayakvad B; Kothari C; Patel C
J Pharm Sci; 2023 May; 112(5):1268-1276. PubMed ID: 36822274
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS Investigation of nitrosamine impurities in certain Sartan group medicinal products available in Istanbul, Türkiye.
Öncü T; Yüksel B; Binay E; Şen N
Ann Pharm Fr; 2024 Jan; 82(1):72-83. PubMed ID: 37567559
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel method for polar metabolite profiling by supercritical fluid chromatography/tandem mass spectrometry.
Konya Y; Izumi Y; Bamba T
J Chromatogr A; 2020 Nov; 1632():461587. PubMed ID: 33059177
[TBL] [Abstract][Full Text] [Related]
10. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
11. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry.
Vogel M; Norwig J
J Pharm Biomed Anal; 2022 Sep; 219():114910. PubMed ID: 35779354
[TBL] [Abstract][Full Text] [Related]
13. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment for nitrosated pharmaceuticals: A future perspective in drug development.
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2022 Apr; 355(4):e2100435. PubMed ID: 35088435
[TBL] [Abstract][Full Text] [Related]
15. Development of an achiral supercritical fluid chromatography method with ultraviolet absorbance and mass spectrometric detection for impurity profiling of drug candidates. Part I: Optimization of mobile phase composition.
Lemasson E; Bertin S; Hennig P; Boiteux H; Lesellier E; West C
J Chromatogr A; 2015 Aug; 1408():217-26. PubMed ID: 26195034
[TBL] [Abstract][Full Text] [Related]
16. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
Tchernev G; Kordeva S
Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
[TBL] [Abstract][Full Text] [Related]
17. Chaotropic Effects in Sub/Supercritical Fluid Chromatography via Ammonium Hydroxide in Water-Rich Modifiers: Enabling Separation of Peptides and Highly Polar Pharmaceuticals at the Preparative Scale.
Liu J; Makarov AA; Bennett R; Haidar Ahmad IA; DaSilva J; Reibarkh M; Mangion I; Mann BF; Regalado EL
Anal Chem; 2019 Nov; 91(21):13907-13915. PubMed ID: 31549812
[TBL] [Abstract][Full Text] [Related]
18. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
[TBL] [Abstract][Full Text] [Related]
19. Two-dimensional supercritical fluid chromatography/mass spectrometry for the enantiomeric analysis and purification of pharmaceutical samples.
Zeng L; Xu R; Zhang Y; Kassel DB
J Chromatogr A; 2011 May; 1218(20):3080-8. PubMed ID: 21489542
[TBL] [Abstract][Full Text] [Related]
20. Development of an achiral supercritical fluid chromatography method with ultraviolet absorbance and mass spectrometric detection for impurity profiling of drug candidates. Part II. Selection of an orthogonal set of stationary phases.
Lemasson E; Bertin S; Hennig P; Boiteux H; Lesellier E; West C
J Chromatogr A; 2015 Aug; 1408():227-35. PubMed ID: 26195036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
